M. E. Garza
View as an RSS Feed
View M. E. Garza's Articles BY TICKER:
ACAR, ACCP, ALKS, ALTH, ALXA, AMPE, AMRN, ANIP, ARIA, ARNA, ARRY, ASTM, ASTX, AVEO, AVNR, BCRX, BLRX, CBLI, CCEL, CDXC, CLDA, CLRB, CLRT, CLSN, CNDO, CORT, CRIS, CTIC, CVM, CYTR, DCTH, DEPO, ECTE, EPCT, EPIX, EXEL, FURX, GALE, GSK, GTHP, HALO, HEB, HLF, IBIO, IDIX, IMMY, IMUC, INCY, INHX, IPCI, KERX, KVPBQ, LGND, MDGN, MEDX, MNTA, MSTX, NAVB, NBIX, NBS, NEPH, NEPT, NPSP, NVAX, NWBO, OCLS, OMPI, ONCS, ONCY, OPK, OXGN, PBTH, PGNX, PLX, POZN, PPHM, PSTI, PVCT, QGEN, RGEN, RNN, RXPC, SGEN, SIGA, SLXP, SNWV, SPPI, SYN, TDLP, THLD, THRX, TKMR, TSPT, VICL, XOMA, YMI, ZLCS
- 5 Biotechs Investors Should Be Watching
- Seattle Genetics: Strong Immunotherapy for Your Portfolio
- New Data Poised to Boost Aastrom Biosciences
- Amarin to Deliver Top-Line Results Ahead of Schedule
- Aastrom Biosciences's Turn: Another Unsubstantiated Biotech Bear Raid
- Talking With Aastrom Biosciences Execs: Previewing Clinical Trial Info
- Movement in Medical Device Small Caps
- 3 Upcoming FDA Decisions to Watch Closely
- Depomed Posts Positive Earnings With Strong 2011 Outlook
- Will Avanir Continue to Trend Higher?
- DepoMed: Positive Pipeline Should Fuel Share Price
- Sanofi-Aventis Buys BMP Sunstone 'To Reinforce Leadership Position in China'
- Aastrom Biosciences Gaining Momentum on Outlook for Positive CLI Trial Results
- Provectus Gains Momentum Ahead of Upcoming Melanoma Data Presentation
- 5 High-Impact Biotech Catalysts to Watch This Week
- Amarin's Potential Blockbuster in the Making
- GE / Clarient Deal Expected to Accelerate Development of New Cancer Diagnosis Tools
- Avanir Addresses Safety Data From Pivotal STAR Trial
- Cleveland BioLabs' Unfounded Fear of Dilution
- Depomed: Long-Term Winner Holding Strong
- What Most Alkerme Investors Really Want
- ImmunoCellular Therapeutics CEO Explains Economic Significance of New Vaccine Manufacturing Method
- Six Reasons to Like Pluristem Therapeutics
- RXi Pharmaceuticals: What's Cooking?
- Will Access Pharma Keep Trending Higher?
- Several Scenarios Ahead of the FDA's Imminent Decision on Alexza
- Healthcare Headlines: Santarus Rallies, Amgen Announces Results
- Can Array BioPharma Attract Yet Another Partner?
- Investment Risk in Cleveland BioLabs Has Been Wiped Off the Table
- Bullish Trends at Keryx Biopharmaceuticals
- Biotechs With Room to Run
- Three Biotech Stocks With Pending News Developments, Catalysts